A CD40-CD154 interaction in tissue fibrosis

Arthritis and Rheumatism

Volumn 58, Issue 11, 2008, Pages 3562-3573

  Kawai, Masataka ^a   Masuda, Ayako ^a   Kuwana, Masataka ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CD40 ANTIGEN; CD40 LIGAND; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL INTERACTION; CELL PROLIFERATION; CONTROLLED STUDY; ELECTRON MICROSCOPE; FEMALE; GENE EXPRESSION REGULATION; GENE TRANSFER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; LYMPHOCYTIC INFILTRATION; MAST CELL; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SKIN FIBROBLAST; SKIN FIBROSIS; SYSTEMIC SCLEROSIS;

ANIMALS; ANTIGENS, CD40; BLEOMYCIN; CD40 LIGAND; CELL ADHESION MOLECULES; CELLS, CULTURED; CHEMOKINE CCL2; CHEMOKINE CCL5; FIBROBLASTS; FIBROSIS; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MAST CELLS; MICE; SCLERODERMA, SYSTEMIC; UP-REGULATION;

EID: 55849109623     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.23994     Document Type: Article

References (38)

1. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67.
2. LeRoy EC. Systemic sclerosis: a vascular perspective. Rheum Dis Clin North Am 1996;22:675-94.
3. Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992;166:255-63.
4. Laman JD, Claassen E, Noelle RJ. Functions of CD40 and its ligand, gp39 (CD40L). Crit Rev Immunol 1996;16:59-108.
5. Van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000;67:2-17.
6. Fukasawa C, Kawaguchi Y, Harigai M, Sugiura T, Takagi K, Kawamoto M, et al. Increased CD40 expression in skin fibroblasts from patients with systemic sclerosis (SSc): role of CD40-CD154 in the phenotype of SSc fibroblasts. Eur J Immunol 2003;33:2792-800.
7. Allanore Y, Borderie D, Meune C, Lemarechal H, Weber S, Ekindjian OG, et al. Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers. Ann Rheum Dis 2005;64:481-3.
8. Komura K, Fujimoto M, Matsushita T, Yanaba K, Kodera M, Kawasuji A, et al. Increased serum soluble CD40 levels in patients with systemic sclerosis. J Rheumatol 2007;34:353-8.
9. Nakamura M, Tanaka Y, Satoh T, Kawai M, Hirakata M, Kaburaki J, et al. Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism. Rheumatology (Oxford) 2006;45:150-6.
10. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, et al. Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999;112:456-62.
11. Ogawa Y, Yamazaki K, Kuwana M, Mashima Y, Nakamura Y, Ishida S, et al. A significant role of stromal fibroblasts in rapidly progressive dry eye in patients with chronic GVHD. Invest Ophthalmol Vis Sci 2001;42:111-9.
12. Woessner JF Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961;93:440-7.
13. Sempowski GD, Rozenblit J, Smith TJ, Phipps RP. Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production. Am J Physiol 1998;274:707-14.
14. Yellin MJ, Winikoff S, Fortune SM, Baum D, Crow MK, Lederman S, et al. Ligation of CD40 on fibroblasts induces CD54 (ICAM-1) and CD106 (VCAM-1) up-regulation and IL-6 production and proliferation. J Leukoc Biol 1995;58:209-16.
15. Gruschwitz M, von den Driesch P, Kellner I, Hornstein OP, Sterry W. Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. J Am Acad Dermatol 1992;27:169-77.
16. Gruschwitz MS, Vieth G. Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-γ and tumor necrosis factor α in the early disease stage. Arthritis Rheum 1997;40:540-50.
17. Needleman BW. Increased expression of intercellular adhesion molecule 1 on the fibroblasts of scleroderma patients. Arthritis Rheum 1990;33:1847-51.
18. Bolster MB, Ludwicka A, Sutherland SE, Strange C, Silver RM. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 1997;40:743-51.
19. Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F, et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004;138:540-6.
20. Duncan MR, Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991;97:686-92.
21. Anders HJ, Vielhauer V, Frink M, Linde Y, Cohen CD, Blattner SM, et al. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest 2002;109:251-9.
22. Tokuda A, Itakura M, Onai N, Kimura H, Kuriyama T, Matsushima K. Pivotal role of CCR1-positive leukocytes in bleomycininduced lung fibrosis in mice. J Immunol 2000;164:2745-51.
23. Distler O, Pap T, Kowal-Bielecka O, Meyringer R, Guiducci S, Landthaler M, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001;44:2665-78.
24. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor β1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996;271:17779-84.
25. Distler JH, Jungel A, Caretto D, Schulze-Horsel U, Kowal-Bielecka O, Gay RE, et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum 2006;54:214-25.
26. Ferreira AM, Takagawa S, Fresco R, Zhu X, Varga J, DiPietro LA. Diminished induction of skin fibrosis in mice with MCP-1 deficiency. J Invest Dermatol 2006;126:1900-8.
27. Yamamoto T, Nishioka K. Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2003;121:510-6.
28. Gruber BL. Mast cells in the pathogenesis of fibrosis. Curr Rheumatol Rep 2003;5:147-53.
29. Trautmann A, Toksoy A, Engelhardt E, Brocker EB, Gillitzer R. Mast cell involvement in normal human skin wound healing: expression of monocyte chemoattractant protein-1 is correlated with recruitment of mast cells which synthesize interleukin-4 in vivo. J Pathol 2000;190:100-6.
30. Yamamoto T, Takahashi Y, Takagawa S, Katayama I, Nishioka K. Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W(V) mice. J Rheumatol 1999;26:2628-34.
31. Yamamoto T, Nishioka K. Animal model of sclerotic skin. IV: induction of dermal sclerosis by bleomycin is T cell independent. J Invest Dermatol 2001;117:999-1001.
32. Komura K, Fujimoto M, Yanaba K, Matsushita T, Matsushita Y, Horikawa M, et al. Blockade of CD40-CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse. Ann Rheum Dis 2008;67:867-72.
33. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, et al, on behalf of the BG9588 Lupus Nephritis Trial Group. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003;48:719-27.
34. Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D, for the IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:3251-8.
35. Kuwana M, Nomura S, Fujimura K, Nagasawa T, Muto Y, Kurata Y, et al. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 2004;103:1229-36.
36. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand [letter]. Nat Med 2000;6:114.
37. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, et al. CD40L stabilizes arterial thrombi by a β3 integrin - dependent mechanism. Nat Med 2002;8:247-52.
38. Kelley SK, Gelzleichter T, Xie D, Lee WP, Darbonne WC, Qureshi F, et al. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol 2006;148:1116-23.